We show that Cbl-b inhibitors are effective as single-agents or in combination with anti-PDL1/PD1 in organoids derived from pre-clinical cancer models, thus these compounds also have the potential to enhance responses to other immunotherapies. This evidence concerns the gene CBLB and cancer.